The FDA has granted Orphan Drug designation to NS-229 for the treatment of eosinophilic granulomatosis with polyangiitis.

Regional Trends Shaping the Idiopathic Pulmonary Fibrosis Management Industry: North America leads with innovation, while Asia-Pacific shows rapid diagnostic adoption and rising treatment demand.” — ...

The author has a $2.75 Price Target on CytoDyn (CYDY) in the Next 6 to 12 months, representing significant upside from its ...

The fast track designation is designed to facilitate the development and expedite the review of drugs that treat serious ...

Qure divested for $25M, advanced AMT-130 with FDA approvals, and building infrastructure. A strong balance sheet backs ...

The FDA granted rare pediatric disease designation for OCU410ST, a gene therapy designed to treat ABCA4-associated ...

POLB 001 has been granted FDA orphan drug designation as a preventative therapy for cytokine release syndrome caused by ...

Recursion Pharmaceuticals RXRX and Schrodinger SDGR are pioneering the use of artificial intelligence (AI) in drug discovery ...

Ocugen's drug to treat retina diseases received a rare pediatric disease designation from U.S. regulators. The biotechnology said Tuesday that the Food and Drug Administration granted the designation ...

The London-based clinical stage biopharmaceutical company targeting diseases said the FDA has granted orphan drug designation to its POLB 001 therapy as an oral preventative treatment for T-cell ...

Candel Therapeutics essentially uses a dual-virus strategy with CAN-2409 and CAN-3110 immunotherapies. Find out why CADL ...